Maxim Group initiated coverage on Acrivon Therapeutics
$ACRV
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Acrivon Therapeutics with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/16/2024 | $16.00 | Neutral → Buy | Ladenburg Thalmann |
| 4/29/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 3/1/2024 | $14.00 | Mkt Outperform | JMP Securities |
| 12/15/2023 | $17.00 → $12.00 | Buy | Jefferies |
| 10/5/2023 | Buy | Maxim Group | |
| 6/2/2023 | $25.00 | Outperform | Oppenheimer |
| 5/8/2023 | $25.00 | Outperform | BMO Capital Markets |
| 4/27/2023 | $22.00 | Buy | Ladenburg Thalmann |
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00
Ladenburg Thalmann downgraded Acrivon Therapeutics from Buy to Neutral
JMP Securities initiated coverage of Acrivon Therapeutics with a rating of Mkt Outperform and set a new price target of $14.00
BMO Capital analyst Etzer Darout reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and maintains $25 price target.
HC Wainwright & Co. analyst Emily Bodnar maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and raises the price target from $20 to $22.
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.84) by 13.1 percent. This is a 25.86 percent decrease over losses of $(0.58) per share from the same period last year.
10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
– Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection (p = 0.009) from ongoing ACR-368 registrational-intent Phase 2b endometrial cancer study presented at ESMO – Endometrial cancer, a tumor type identified by AP3 as particularly sensitive to ACR-368 treatment, represents the first potential approval opportunity for ACR-368, in second line, with options to move into the front-line setting being evaluated – Completed planned enrollment of first dose-escalation cohort in ongoing Phase 1 study of ACR-2316, company's second clinical stage asset, internally discovered using AP3 – Cash, cas
AP3-identified clinical biomarkers for ACR-368 led to the development of a response-predictive OncoSignature assay which has shown statistically significant prospective validation and responder enrichment in the ongoing registrational-intent Phase 2b studyACR-2316, a novel WEE1/PKMYT1 inhibitor, was uniquely enabled and optimized by AP3 to deliver superior single agent activity, complete tumor regression and pro-apoptotic tumor cell death through potent activation of CDK1, CDK2, and PLK1Acrivon scientists to present data at two key scientific conferences demonstrating AP3's proprietary and actionable machine learning-driven capabilities for drug discovery and clinical development WATERTOWN,
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced that the company approved a grant of equity awards under its 2023 Inducement Plan to certain employees. The equity awards were granted in the form of stock options and have a grant date of October 15, 2024. The employees received an aggregate of options to purchase 61,9
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights. "On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors. "Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precisi
WATERTOWN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D., to its board of directors. "We are excited to welcome Ivana to our board of directors," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and fou
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)